X

Trial Profile

A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Futibatinib (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Urogenital cancer
Focus Therapeutic Use
Sponsors Taiho Oncology

Most Recent Events

18 Jun 2024 Planned End Date changed from 30 Jun 2024 to 1 Sep 2025.
18 Jun 2024 Planned primary completion date changed from 1 May 2024 to 1 Aug 2025.
11 Apr 2024 Planned primary completion date changed from 1 Dec 2023 to 1 May 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com